Click here to view online. Add this email to your safelist.

AstraZeneca logo

AstraZeneca announces two new phase IIIb trials for Forxiga in chronic kidney disease and chronic heart failure

12 September 2016

AstraZeneca today announced two new randomised, placebo-controlled Phase IIIb outcome trials with Forxiga (dapagliflozin), an SGLT-2 inhibitor currently indicated for the treatment of type-2 diabetes.

Read more  Read more

RSS Feed  RSS Feed Twitter  Follow us on Twitter
Legal notice and Terms of Use Privacy policy Cookie policy Site map © AstraZeneca 2016

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.